Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2019

May 10, 2019

SELL
$2.41 - $5.91 $125 - $307
-52 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$6.7 - $12.95 $100 - $194
15 Added 40.54%
52 $1,000
Q4 2017

Jan 31, 2018

BUY
$5.07 - $7.92 $187 - $293
37
37 $0

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Resources Investment Advisors, Llc. Portfolio

Follow Resources Investment Advisors, Llc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Resources Investment Advisors, Llc., based on Form 13F filings with the SEC.

News

Stay updated on Resources Investment Advisors, Llc. with notifications on news.